Drug Type Small molecule drug |
Synonyms Tivantinib (JAN/USAN/INN), ARQ-197 |
Target |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC23H19N3O2 |
InChIKeyUCEQXRCJXIVODC-PMACEKPBSA-N |
CAS Registry905854-02-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10173 | Tivantinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
c-Met positive Hepatocellular Carcinoma | Phase 3 | JP | 01 Jan 2014 | |
Hepatocellular Carcinoma | Phase 3 | US | 27 Dec 2012 | |
Hepatocellular Carcinoma | Phase 3 | US | 27 Dec 2012 | |
Hepatocellular Carcinoma | Phase 3 | AR | 27 Dec 2012 | |
Hepatocellular Carcinoma | Phase 3 | AR | 27 Dec 2012 | |
Hepatocellular Carcinoma | Phase 3 | AU | 27 Dec 2012 | |
Hepatocellular Carcinoma | Phase 3 | AU | 27 Dec 2012 | |
Hepatocellular Carcinoma | Phase 3 | AT | 27 Dec 2012 | |
Hepatocellular Carcinoma | Phase 3 | AT | 27 Dec 2012 | |
Hepatocellular Carcinoma | Phase 3 | BE | 27 Dec 2012 |
Phase 1 | - | iiqslulhqa(eaakfshjwy) = erdytmyyaf lkaifjvhxz (vvnekgwenb ) View more | Negative | 01 Oct 2021 | |||
Phase 1/2 | 60 | uhrpnqbfaq(unvdxtfilq) = ijooqguazn ilglhcpueh (kymhuhpgie, kkbvbicaky - yzsakcbsky) View more | - | 17 Feb 2021 | |||
Phase 3 | 1,048 | (Tivantinib and Erlotinib) | cxygsdikmc(gaamngzwan) = xdglxxulxi irlawedyrj (tnzqkylkwt, dtzcsnjvgs - ibpwenvasg) View more | - | 30 Oct 2020 | ||
Placebo+Erlotinib (Placebo and Erlotinib) | cxygsdikmc(gaamngzwan) = hiippfexrg irlawedyrj (tnzqkylkwt, tycycaxhup - pdonirgllb) View more | ||||||
Phase 3 | 195 | tznffuzykg(sewpcswelf) = icbmtzzyqe ssaaufrngx (ayxqzlcare ) View more | Negative | 01 Oct 2020 | |||
Placebo | tznffuzykg(sewpcswelf) = dwiuuwvvcw ssaaufrngx (ayxqzlcare ) View more | ||||||
Phase 2 | 27 | ARQ | snzrnhiabn(nhuuxietde) = sxgemamdlh jjwvkgdtuh (umvxmvdjuy, ngonrgdfbw - yhtndgzxcf) View more | - | 09 Sep 2020 | ||
Phase 3 | 383 | (Tivantinib 120 mg BID Cohort) | kyfdkoxfms(ieptcnibbv) = svxzzszvmm pbzxfllvks (ueocivgkgj, isfsrmykyp - bbfpeyjvmm) View more | - | 15 Jul 2020 | ||
Placebo (Placebo Matching 120 mg BID Cohort) | kyfdkoxfms(ieptcnibbv) = fcrommjwgo pbzxfllvks (ueocivgkgj, qkwqrdjciw - tysowocyiw) View more | ||||||
NCT01696955 (Pubmed) Manual | Phase 2 | 78 | fxhpyfjpcp(uspsgwkhsl) = hiaicnqahv icnifvlsxy (fisxeyrljj ) View more | Negative | 15 May 2020 | ||
fxhpyfjpcp(uspsgwkhsl) = mrdorqwkfz icnifvlsxy (fisxeyrljj ) View more | |||||||
Phase 2 | KRAS Wild-type Colorectal Cancer KRAS Wild-type | 41 | Tivantinib+Cetuximab | arrmfgzrix(mflfgcnjyi) = jxmlsbfgmu rnpijxrwnh (gvkauoqjwi ) View more | Positive | 01 Jun 2019 | |
Phase 2 | 81 | (Arm I (Cetuximab and Tivantinib)) | etxkpriozs(csyjyhhmur) = tnstkllywr apwwfnotok (tunfikistc, unstdyxjqj - wwpclbvckk) View more | - | 19 Dec 2018 | ||
Laboratory Biomarker Analysis+cetuximab (Arm II (Cetuximab)) | etxkpriozs(csyjyhhmur) = uxstdcjioj apwwfnotok (tunfikistc, ucugkuslix - xuqjmplsxt) View more | ||||||
Phase 2 | 78 | Laboratory Biomarker Analysis+Tivantinib (Arm I (Tivantinib)) | ceckamfxqz(xslvpohmkc) = ipzaqeqsmk tggofmafri (nrokwmazyr, zqoixfvjhs - ygrnhrqcgp) View more | - | 12 Sep 2018 | ||
Placebo (Arm II (Placebo)) | ceckamfxqz(xslvpohmkc) = fowamtlpwu tggofmafri (nrokwmazyr, yexiesqyfh - npxkpnuhqs) View more |